HLA-DRB1 Kit ELISA

N° du produit ABIN2948352

Détail du produit HLA-DRB1 Kit ELISA

Antigène: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Reactivité: Humain

Méthode de détection: Colorimetric

Type de méthode: Competition ELISA

Gamme de detection: 0.78 ng/mL - 50 ng/mL

Seuil minimal de détection: 0.78 ng/mL

Application: ELISA

Fonction: Human HLA class II histocompatibility antigen, DRB1-15 beta chain ELISA Kit is an ELISA kit against Human HLA class II histocompatibility antigen, DRB1-15 beta chain (HLA-DRB1-15).

Type d'échantillon: Plasma, Serum

Analytical Method: Quantitative

Attributs du produit: HLA class II histocompatibility antigen, DRB1-15 beta chain

Information d'application

Indications d'application:

Stability: The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5 % within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.

Recommended dilutions: Optimal dilutions/concentrations should be determined by the end user.

Plaque: Pre-coated

Restrictions: For Research Use only

Stockage

Stock: 4 °C/-20 °C

Stockage commentaire: Upon receipt, store the kit according to the storage instruction in the kit's manual.

Date de péremption: 6 months

Détail du antigène

Antigène: HLA-DRB1 (Major Histocompatibility Complex, Class II, DR beta 1 (HLA-DRB1))

Autre désignation: HLA Class II Histocompatibility Antigen, DRB1-15 beta Chain (HLA-DRB1 Produits)

Synonymes: MGC108235 Kit ELISA, DRB1 Kit ELISA, DRw10 Kit ELISA, HLA-DR1B Kit ELISA, HLA-DRB Kit ELISA, SS1 Kit ELISA, major histocompatibility complex, class II, DR beta 1 Kit ELISA, hla-drb1 Kit ELISA, HLA-DRB1 Kit ELISA

Pathways: TCR Signaling, Positive Regulation of Peptide Hormone Secretion, Production of Molecular Mediator of Immune Response, CXCR4-mediated Signaling Events, Cancer Immune Checkpoints